Grace Therapeutics (GRCE) vs. Its Rivals Financial Contrast

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Grace Therapeutics to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares Grace Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Grace Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8408	22247	50400	1349	2.54

Grace Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 500.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 252.08%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Grace Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Grace Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.72
Grace Therapeutics Competitors	$9.89 billion	$136.37 million	-5.51

Grace Therapeutics’ peers have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Grace Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ peers have a beta of 3.86, indicating that their average share price is 286% more volatile than the S&P 500.

Summary

Grace Therapeutics beats its peers on 7 of the 13 factors compared.

Grace Therapeutics Company Profile

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.